ANI Pharmaceuticals posts Q3 2025 results update

ANI Pharmaceuticals, Inc. filed a current report to note that it has released its financial results for the third quarter ended September 30, 2025.

Rhea-AI Filing Summary

ANI Pharmaceuticals, Inc. filed a current report to note that it has released its financial results for the third quarter ended September 30, 2025. The company announced these results in a press release dated November 7, 2025, which is included as Exhibit 99.1. The report clarifies that the information about these quarterly results is being furnished rather than filed, meaning it is not subject to certain liability provisions under securities law unless specifically incorporated into other filings.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ANI Pharmaceuticals (ANIP) disclose in this 8-K?

ANI Pharmaceuticals disclosed that it issued a press release announcing its financial results for the third quarter ended September 30, 2025, and attached that press release as Exhibit 99.1.

Which period’s results are covered in ANI Pharmaceuticals’ latest press release?

The press release furnished by ANI Pharmaceuticals covers its financial results for the third quarter ended September 30, 2025.

How did ANI Pharmaceuticals provide its Q3 2025 results to investors?

ANI Pharmaceuticals provided its Q3 2025 results through a press release dated November 7, 2025, which is furnished as Exhibit 99.1 to the current report.

Is the ANI Pharmaceuticals Q3 2025 press release considered filed with the SEC?

The company states that the information in Item 2.02, including the Q3 2025 press release, is furnished and not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, unless specifically incorporated by reference elsewhere.

Who signed the ANI Pharmaceuticals 8-K related to Q3 2025 results?

The report was signed on behalf of ANI Pharmaceuticals, Inc. by Stephen P. Carey, Senior Vice President Finance and Chief Financial Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/07/2025 - 06:54 AM Learn about SEC filing dates

0001023024FALSE00010230242025-11-072025-11-07

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

FORM 8-K 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): November 7, 2025

ANI PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware			001-31812			58-2301143
(State or other jurisdiction of incorporation)			(Commission File Number)			(I.R.S. Employer Identification No.)

210 Main Street West Baudette, Minnesota			56623
(Address of principal executive offices)			(Zip Code)

Registrant's telephone number, including area code: (218) 634-3500

Not Applicable

(Former name or former address, if changed since last report.)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock			ANIP			Nasdaq Stock Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02 Results of Operations and Financial Condition

On November 7, 2025, ANI Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1.*

Item 9.01 Exhibits

(d)Exhibits

Exhibit No.			Description
99.1			Press Release of the Company, dated November 7, 2025
104			Cover Page Interactive Data File (embedded with the Inline XBRL document)

*The information in Item 2.02 of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 7, 2025			ANI PHARMACEUTICALS, INC.
			By:			/s/ Stephen P. Carey
			Name:			Stephen P. Carey
			Title:			Senior Vice President Finance and Chief Financial Officer